salo glp-1 reviews Frontiers In the gray world of

Ogata, S., Misumi, Y., Tsuji, E., Takami, N., Oda, K., and Ikehara, Y

Studies of the same species also varied, with a follow-up of patients treated with GLP-1RAs (74) showing no significant difference in calcitonin concentrations between liraglutide and placebo and no change in the risk of thyroid C-cell tumors

doi: 10.1111/1751-7915.14293 80 WahlstrmASayinSIMarschallH-UBckhedF

Mori H, Kuroda A, Yoshida S, et al

Thats right in line with the results doctors are seeing from the injectable Wegovy

Special Population Considerations Population pharmacokinetic analyses revealed: Body weight influences GLP2 exposure (approximately 1.1% change per kg) Renal impairment (including end-stage renal disease) does not significantly impact pharmacokinetics Hepatic impairment (mild to severe) does not require dose adjustments Age, sex, race, and ethnicity do not have clinically relevant effects on GLP2 pharmacokinetics Study Populations GLP2 clinical research has included the following participant groups: Adults with type 2 diabetes Primary focus of SURPASS trials (over 6,000 participants) Adults with obesity or overweight SURMOUNT trials for chronic weight management Participants with metabolic comorbidities Including metabolic syndrome, prediabetes Heart failure patients with HFpEF and obesity SUMMIT trial population Adults with obstructive sleep apnea and obesity SURMOUNT-OSA studies Various demographic populations Multinational studies across diverse racial and ethnic groups Research Limitations & Regulatory Status Critical Gaps in Current Evidence Despite an extensive clinical development program, important limitations remain in the GLP2 evidence base